• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Discovery Stage Partnering Terms and Agreements Product Image

Discovery Stage Partnering Terms and Agreements

  • ID: 650934
  • March 2015
  • Region: Global
  • 3998 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • 3SBio
  • Bayer CropScience
  • Daiichi Sankyo
  • Grifols
  • Novartis
  • Sanofi
  • MORE

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 3,000 links to online copies of actual discovery stage deals and contract documents as submitted to READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3SBio
  • Bayer CropScience
  • Daiichi Sankyo
  • Grifols
  • Novartis
  • Sanofi
  • MORE

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Why do companies partner at discovery stage?

2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals

Chapter 3 – Discovery stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte – Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier – GeNeuro
3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter – Onconova Therapeutics
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Pfizer – Spark Therapeutics
3.6.1.b. Case study : Contrafect – Trellis Bioscience
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study: Tracon –Boehringer Ingelheim – Macrogenics
3.7.1.b. Case study: Fibrocell Science – Intrexon

Chapter 4 – Discovery stage partnering payment strategies

4.1. Introduction
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 – Trends in discovery stage deal making

5.1. Introduction
5.2. Discovery stage partnering over the years
5.2.1.. Attributes of discovery deals
5.3. Big pharma discovery stage dealmaking activity
5.4. Big biotech discovery stage dealmaking activity
5.5. Discovery stage partnering by deal type
5.6. Discovery stage partnering by disease type
5.7. Discovery stage partnering by technology type

Chapter 6 – Average payment terms for discovery stage partnering

6.1. Introduction
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
Figure 17: Discovery stage deals with a headline value- 2010
Figure 18: Discovery stage deals with a headline value- 2011
Figure 19: Discovery stage deals with a headline value- 2012
Figure 20: Discovery stage deals with a headline value- 2013
Figure 21: Discovery stage deals with a headline value- 2014
Figure 22: Discovery stage deals with a headline value- 2015
Figure 23: Discovery stage deal headline value distribution, US$million
Figure 24: Summary median headline value for discovery stage of development, 2010-2015
6.4.2. Discovery stage upfront payments
Figure 25: Discovery stage deals with upfront payment values– 2010
Figure 26: Discovery stage deals with upfront payment values- 2011
Figure 27: Discovery stage deals with upfront payment values- 2012
Figure 28: Discovery stage deals with upfront payment values- 2013
Figure 29: Discovery stage deals with upfront payment values- 2014
Figure 30: Discovery stage deals with upfront payment values- 2015
Figure 31: Discovery stage deal upfront payment distribution, US$million
Figure 32: Summary median upfront payments discovery stage of development, 2010-2015
6.4.3. Discovery stage milestone payments
Figure 33: Discovery stage deals with milestone payments -2010
Figure 34: Discovery stage deals with milestone payments -2011
Figure 35: Discovery stage deals with milestone payments -2012
Figure 36: Discovery stage deals with milestone payments -2013
Figure 37: Discovery stage deals with milestone payments -2014
Figure 38: Discovery stage deals with milestone payments -2015
Figure 39: Discovery stage deal milestone distribution, US$million
6.4.4. Discovery stage royalty rates
Figure 40: Discovery stage deals with royalty rates, %- 2010
Figure 41: Discovery stage deals with royalty rates, %- 2011
Figure 42: Discovery stage deals with royalty rates, %- 2012
Figure 43: Discovery stage deals with royalty rates, %- 2013
Figure 44: Discovery stage deals with royalty rates, %- 2014
Figure 45: Discovery stage deals with royalty rates, %- 2015
Figure 46: Discovery stage deal royalty rate distribution, US$million
Figure 47: Summary median royalty rate for discovery stage of development, 2010-2015

Chapter 7 – Leading discovery stage deals

7.1. Introduction
7.2. Top discovery stage deals by value

Chapter 8 – Big pharma and big biotech discovery stage partnering deals

8.1. Introduction
8.2. How to use big pharma/big biotech discovery stage partnering deals
8.3. Big pharma discovery stage partnering company profiles
8.4. Big biotech discovery stage partnering company profiles

Chapter 9 – Discovery stage partnering contracts directory

9.1. Introduction
9.2. Company A-Z
9.3. By deal type
9.4. By therapy area

Chapter 10 – Discovery stage dealmaking directory by year

10.1. Introduction
10.2. Discovery stage deals - 2010
10.3. Discovery stage deals - 2011
10.4. Discovery stage deals - 2012
10.5. Discovery stage deals - 2013
10.6. Discovery stage deals - 2014
10.7. Discovery stage deals - 2015
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Upgrades to subscription access products
Order Form – Reports

View the accompanying volume for:

Appendices
Introduction
Appendix 1 – Directory of discovery stage deals by company A-Z 2010-2015
Appendix 2 – Directory of discovery stage deals by deal type 2010-2015
Appendix 3 – Directory of discovery stage deals by therapy area 2010-2015
Appendix 4 – Partnering resource center
Online partnering
Partnering events
Further reading on dealmaking

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2010-2015), % of all deals where stage disclosed
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for discovery stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Discovery stage partnering frequency 2010-2015
Figure 7: Big pharma – top 50 – discovery stage deals 2010 to 2015
Figure 8: Big pharma discovery stage deal frequency – 2010 to 2015
Figure 9: Big biotech – top 50 – discovery stage deals 2010 to 2015
Figure 10: Big biotech discovery stage deal frequency – 2010 to 2015
Figure 11: Discovery stage partnering by deal type since 2010
Figure 12: Discovery stage partnering by disease type since 2010
Figure 13: Discovery stage partnering by technology type since 2010
Figure 14: Review of median upfront payments for discovery stage deals
Figure 15: Review of median milestone payments for discovery stage deals
Figure 16: Review of median royalty payments for discovery stage deals
Figure 17: Discovery stage deals with a headline value- 2010
Figure 18: Discovery stage deals with a headline value- 2011
Figure 19: Discovery stage deals with a headline value- 2012
Figure 20: Discovery stage deals with a headline value- 2013
Figure 21: Discovery stage deals with a headline value- 2014
Figure 22: Discovery stage deals with a headline value- 2015
Figure 23: Discovery stage deal headline value distribution, US$million
Figure 24: Summary median headline value for discovery stage of development, 2010-2015
Figure 25: Discovery stage deals with upfront payment values– 2010
Figure 26: Discovery stage deals with upfront payment values- 2011
Figure 27: Discovery stage deals with upfront payment values- 2012
Figure 28: Discovery stage deals with upfront payment values- 2013
Figure 29: Discovery stage deals with upfront payment values- 2014
Figure 30: Discovery stage deals with upfront payment values- 2015
Figure 31: Discovery stage deal upfront payment distribution, US$million
Figure 32: Summary median upfront payments discovery stage of development, 2010-2015
Figure 33: Discovery stage deals with milestone payments -2010
Figure 34: Discovery stage deals with milestone payments -2011
Figure 35: Discovery stage deals with milestone payments -2012
Figure 36: Discovery stage deals with milestone payments -2013
Figure 37: Discovery stage deals with milestone payments -2014
Figure 38: Discovery stage deals with milestone payments -2015
Figure 39: Discovery stage deal milestone distribution, US$million
Figure 40: Discovery stage deals with royalty rates, %- 2010
Figure 41: Discovery stage deals with royalty rates, %- 2011
Figure 42: Discovery stage deals with royalty rates, %- 2012
Figure 43: Discovery stage deals with royalty rates, %- 2013
Figure 44: Discovery stage deals with royalty rates, %- 2014
Figure 45: Discovery stage deals with royalty rates, %- 2015
Figure 46: Discovery stage deal royalty rate distribution, US$million
Figure 47: Summary median royalty rate for discovery stage of development, 2010-2015
Figure 48: Top discovery stage deals that exceeds $1 billion in deal value since 2010

Note: Product cover images may vary from those shown

Abbott
Abbvie
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Bayer Animal Health
Bayer CropScience
Bayer Healthcare
Bayer Innovation
Bayer Schering Pharma
Bayer Technology Services
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Chugai Pharmaceutical
CSL
CSL Biotherapies
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eisai Inc
Eli Lilly
Endo Pharmaceuticals
Fresenius
Fresenius Kabi Pharmaceuticals
Gilead Sciences
GlaxoSmithKline
Grifols
Johnson & Johnson
Janssen Research & Development
Janssen Biotech
Kyowa Hakko Kirin
Kyowa Hakko Kirin California
Lundbeck
Lundbeck Foundation
Merck & Co
Merck Sharpe & Dohme
Merck KGaA
Merck Serono
Mitsubishi Tanabe
Novartis
Novartis Institute for Tropical Diseases
Novartis Molecular Diagnostics
Novartis Venture Funds
Novo Nordisk
Otsuka
Pfizer
Pfizer Animal Health
Roche
Roche Applied Science
Roche Diagnostics
Roche Institute for Research and Translational Medicine
Roche Molecular Systems
Roche NimbleGen
Sanofi
Sanofi-Aventis
Sanofi-Pasteur
Servier
Shionogi
Shire
Shire Human Genetic Therapies
Takeda
Takeda Cambridge
Takeda San Francisco
Teva
UCB
Valeant
3SBio
Actelion
Alexion Pharmaceuticals
Array Biopharma
Bavarian Nordic
Biocon
Cangene
Cubist
Dendreon
Elan
Emergent BioSolutions
Galapagos
Genmab
Grifols
Ipsen
Isis Pharmaceuticals
Medivation
Morphosys
Onyx Pharmaceuticals
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
Seattle Genetics
Swedish Orphan Biovitrum
United Therapeutics
Vertex Pharmaceuticals

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

AB Sciex Eli Lilly and Company B. Braun Melsungen AG Astellas Pharma, Inc. Hologic Corporation Merck & Co., Inc.